Myasthenia Gravis and COVID-19: Clinical Characteristics and Outcomes

Myasthenia gravis (MG), an autoimmune neuromuscular disorder, may be a risk factor for severe COVID-19. We conducted an observational retrospective study with 15 consecutive adult MG patients admitted with COVID-19 at four hospitals in São Paulo, Brazil. Most patients with MG hospitalized for COVID-...

Descripción completa

Detalles Bibliográficos
Autores principales: Camelo-Filho, Antonio E., Silva, André M. S., Estephan, Eduardo P., Zambon, Antônio A., Mendonça, Rodrigo H., Souza, Paulo V. S., Pinto, Wladimir B. V. R., Oliveira, Acary S. B., Dangoni-Filho, Iron, Pouza, Ana F. P., Valerio, Berenice C. O., Zanoteli, Edmar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7516054/
https://www.ncbi.nlm.nih.gov/pubmed/33013676
http://dx.doi.org/10.3389/fneur.2020.01053
_version_ 1783586928847749120
author Camelo-Filho, Antonio E.
Silva, André M. S.
Estephan, Eduardo P.
Zambon, Antônio A.
Mendonça, Rodrigo H.
Souza, Paulo V. S.
Pinto, Wladimir B. V. R.
Oliveira, Acary S. B.
Dangoni-Filho, Iron
Pouza, Ana F. P.
Valerio, Berenice C. O.
Zanoteli, Edmar
author_facet Camelo-Filho, Antonio E.
Silva, André M. S.
Estephan, Eduardo P.
Zambon, Antônio A.
Mendonça, Rodrigo H.
Souza, Paulo V. S.
Pinto, Wladimir B. V. R.
Oliveira, Acary S. B.
Dangoni-Filho, Iron
Pouza, Ana F. P.
Valerio, Berenice C. O.
Zanoteli, Edmar
author_sort Camelo-Filho, Antonio E.
collection PubMed
description Myasthenia gravis (MG), an autoimmune neuromuscular disorder, may be a risk factor for severe COVID-19. We conducted an observational retrospective study with 15 consecutive adult MG patients admitted with COVID-19 at four hospitals in São Paulo, Brazil. Most patients with MG hospitalized for COVID-19 had severe courses of the disease: 87% were admitted in the intensive care unit, 73% needed mechanical ventilation, and 30% died. Immunoglobulin use and the plasma exchange procedure were safe. Immunosuppressive therapy seems to be associated with better outcomes, as it might play a protective role.
format Online
Article
Text
id pubmed-7516054
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-75160542020-10-02 Myasthenia Gravis and COVID-19: Clinical Characteristics and Outcomes Camelo-Filho, Antonio E. Silva, André M. S. Estephan, Eduardo P. Zambon, Antônio A. Mendonça, Rodrigo H. Souza, Paulo V. S. Pinto, Wladimir B. V. R. Oliveira, Acary S. B. Dangoni-Filho, Iron Pouza, Ana F. P. Valerio, Berenice C. O. Zanoteli, Edmar Front Neurol Neurology Myasthenia gravis (MG), an autoimmune neuromuscular disorder, may be a risk factor for severe COVID-19. We conducted an observational retrospective study with 15 consecutive adult MG patients admitted with COVID-19 at four hospitals in São Paulo, Brazil. Most patients with MG hospitalized for COVID-19 had severe courses of the disease: 87% were admitted in the intensive care unit, 73% needed mechanical ventilation, and 30% died. Immunoglobulin use and the plasma exchange procedure were safe. Immunosuppressive therapy seems to be associated with better outcomes, as it might play a protective role. Frontiers Media S.A. 2020-09-11 /pmc/articles/PMC7516054/ /pubmed/33013676 http://dx.doi.org/10.3389/fneur.2020.01053 Text en Copyright © 2020 Camelo-Filho, Silva, Estephan, Zambon, Mendonça, Souza, Pinto, Oliveira, Dangoni-Filho, Pouza, Valerio and Zanoteli. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Camelo-Filho, Antonio E.
Silva, André M. S.
Estephan, Eduardo P.
Zambon, Antônio A.
Mendonça, Rodrigo H.
Souza, Paulo V. S.
Pinto, Wladimir B. V. R.
Oliveira, Acary S. B.
Dangoni-Filho, Iron
Pouza, Ana F. P.
Valerio, Berenice C. O.
Zanoteli, Edmar
Myasthenia Gravis and COVID-19: Clinical Characteristics and Outcomes
title Myasthenia Gravis and COVID-19: Clinical Characteristics and Outcomes
title_full Myasthenia Gravis and COVID-19: Clinical Characteristics and Outcomes
title_fullStr Myasthenia Gravis and COVID-19: Clinical Characteristics and Outcomes
title_full_unstemmed Myasthenia Gravis and COVID-19: Clinical Characteristics and Outcomes
title_short Myasthenia Gravis and COVID-19: Clinical Characteristics and Outcomes
title_sort myasthenia gravis and covid-19: clinical characteristics and outcomes
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7516054/
https://www.ncbi.nlm.nih.gov/pubmed/33013676
http://dx.doi.org/10.3389/fneur.2020.01053
work_keys_str_mv AT camelofilhoantonioe myastheniagravisandcovid19clinicalcharacteristicsandoutcomes
AT silvaandrems myastheniagravisandcovid19clinicalcharacteristicsandoutcomes
AT estephaneduardop myastheniagravisandcovid19clinicalcharacteristicsandoutcomes
AT zambonantonioa myastheniagravisandcovid19clinicalcharacteristicsandoutcomes
AT mendoncarodrigoh myastheniagravisandcovid19clinicalcharacteristicsandoutcomes
AT souzapaulovs myastheniagravisandcovid19clinicalcharacteristicsandoutcomes
AT pintowladimirbvr myastheniagravisandcovid19clinicalcharacteristicsandoutcomes
AT oliveiraacarysb myastheniagravisandcovid19clinicalcharacteristicsandoutcomes
AT dangonifilhoiron myastheniagravisandcovid19clinicalcharacteristicsandoutcomes
AT pouzaanafp myastheniagravisandcovid19clinicalcharacteristicsandoutcomes
AT valeriobereniceco myastheniagravisandcovid19clinicalcharacteristicsandoutcomes
AT zanoteliedmar myastheniagravisandcovid19clinicalcharacteristicsandoutcomes

Ejemplares similares